autologous anti-B7-H3 CAR-iC9-expressing T lymphocytes

{
  "id": "MLC-T-ONC-011329",
  "term": "autologous anti-B7-H3 CAR-iC9-expressing T lymphocytes",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and the suicide gene inducible caspase 9 (iCasp9 or iC9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-B7-H3 CAR-iC9-expressing T lymphocytes specifically target and bind to B7-H3-expressing tumor cells, resulting in tumor cell lysis. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis. The iCasp9 safety switch consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered CAR T cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the FKBP12-F36V drug-binding domain, activates caspase 9 and results in apoptosis of the administered CAR T cells.",
  "synonyms": [
    "autologous anti-B7-H3 CAR-iC9-expressing T cells",
    "autologous anti-B7-H3 CAR-iCasp9-expressing T Cells",
    "autologous iC9-B7-H3 CAR-T cells",
    "iC9-CAR.B7-H3 T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-b7-h3-car-ic9-expressing-t-lymphocytes/"
}